💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dexlansoprazole

CHEMBL1201863 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
369.4 g/mol
LogP
2.8
Phase
4

A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.

Молекулярная масса

369,4000 g/mol

LogP

2,80

TPSA

87,10 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Pain Management Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Infectious Disease Gastroesophageal Reflux Disease Lymphoma Type 2 Diabetes Breast Cancer Gout Chronic Pain Colorectal Cancer

Механизм действия

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1

                

                

                
                

                    
InChI

                    
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H14F3N3O2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
Вращаемые Связи

                        
5

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Dexlansoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201863.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9578005.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.